AQR Capital Management LLC Has $354.07 Million Stake in Gilead Sciences, Inc. (GILD)

AQR Capital Management LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 25.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,213,046 shares of the biopharmaceutical company’s stock after buying an additional 1,066,172 shares during the period. AQR Capital Management LLC owned about 0.40% of Gilead Sciences worth $354,070,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Keel Point LLC boosted its position in shares of Gilead Sciences by 0.4% during the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 11 shares during the last quarter. Abner Herrman & Brock LLC lifted its holdings in Gilead Sciences by 0.5% during the first quarter. Abner Herrman & Brock LLC now owns 10,202 shares of the biopharmaceutical company’s stock worth $693,000 after acquiring an additional 50 shares during the period. ARS Investment Partners LLC lifted its holdings in Gilead Sciences by 0.9% during the first quarter. ARS Investment Partners LLC now owns 5,610 shares of the biopharmaceutical company’s stock worth $381,000 after acquiring an additional 50 shares during the period. Blue Fin Capital Inc. lifted its holdings in Gilead Sciences by 0.8% during the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock worth $489,000 after acquiring an additional 55 shares during the period. Finally, McKinley Carter Wealth Services Inc. lifted its holdings in Gilead Sciences by 1.3% during the first quarter. McKinley Carter Wealth Services Inc. now owns 4,986 shares of the biopharmaceutical company’s stock worth $339,000 after acquiring an additional 63 shares during the period. 74.05% of the stock is currently owned by institutional investors.

In related news, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. In the last three months, insiders sold 466,819 shares of company stock valued at $36,740,240. Corporate insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “AQR Capital Management LLC Has $354.07 Million Stake in Gilead Sciences, Inc. (GILD)” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.truebluetribune.com/2017/09/17/aqr-capital-management-llc-acquires-1066172-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.09% on Friday, reaching $82.36. The company’s stock had a trading volume of 12,401,948 shares. The firm has a 50-day moving average of $77.16 and a 200-day moving average of $70.20. The company has a market capitalization of $107.56 billion, a PE ratio of 8.95 and a beta of 1.19. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the prior year, the company posted $3.08 EPS. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. Analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

A number of analysts recently commented on GILD shares. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Jefferies Group LLC reiterated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a report on Tuesday, July 4th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price target on the stock. in a report on Wednesday, June 21st. Deutsche Bank AG started coverage on Gilead Sciences in a report on Friday, June 23rd. They set a “buy” rating and a $79.00 price target on the stock. Finally, Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a research note on Monday, July 17th. Eleven analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $83.79.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply